Veraxa Biotech (VRXA) CEO Antz files Form 3 with no share trades

Rhea-AI Filing Summary

Veraxa Biotech Holding AG director and Chief Executive Officer Christoph Rudiger Antz has filed an initial Form 3 as an insider of the company. The filing identifies his roles but does not report any transactions or share holdings, with all transaction and holding counts shown as zero.

Key Terms

Form 3, Chief Executive Officer, derivativeSummary

3 terms

Form 3 regulatory

"has filed an initial Form 3 as an insider of the company"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Chief Executive Officer financial

"director and Chief Executive Officer Christoph Rudiger Antz"

A chief executive officer (CEO) is the top leader of a company, responsible for making major decisions, setting goals, and guiding the organization’s overall direction. Think of the CEO as the captain of a ship, steering it toward success. Investors pay close attention to the CEO because their leadership and strategy can significantly influence the company's performance and future growth.

derivativeSummary financial

"The Form 3 lists a derivativeSummary section, but it is empty"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 06/23/2026 - 08:54 AM Accepted by SEC EDGAR 06/09/2026 - 07:55 PM Learn about SEC filing dates

FAQ

What does the Veraxa Biotech (VRXA) Form 3 filing show?

The Form 3 shows that Christoph Rudiger Antz is a director and Chief Executive Officer of Veraxa Biotech Holding AG. It is an initial insider ownership report and lists no transactions or share holdings for him in this filing.

Did Veraxa Biotech (VRXA) CEO Christoph Rudiger Antz buy or sell shares?

In this Form 3, Christoph Rudiger Antz reports no share purchases or sales. All transaction counts, including buys, sells, exercises, gifts, and tax withholdings, are listed as zero in the transaction summary section.

Does the Veraxa Biotech (VRXA) Form 3 disclose any current share holdings?

The Form 3’s summary shows no reported holdings, with holding entries set to zero. This means the filing, as presented, does not list any specific number of Veraxa Biotech shares or derivatives currently attributed to the reporting person.

Who is the reporting person in the Veraxa Biotech (VRXA) Form 3?

The reporting person is Christoph Rudiger Antz, identified as both a director and Chief Executive Officer of Veraxa Biotech Holding AG. The filing classifies him as an insider but does not show that he is a ten percent owner.

Does the Veraxa Biotech (VRXA) Form 3 include derivative securities information?

The Form 3 lists a derivativeSummary section, but it is empty in this filing. The transaction summary also shows zero derivative transactions and zero exercised shares, indicating no derivative activity is reported here.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Antz Christoph Rudiger

(Last) (First) (Middle)

TALACKER 35

(Street)

ZURICH 8001

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/09/2026

3. Issuer Name and Ticker or Trading Symbol
Veraxa Biotech Holding AG [ VRXA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Christoph Antz	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)